In this study, we examined the anti-tumor effect of the inhibitors of the ATR-Chk1 or ATM-Chk2 pathway in endometrial cancer cells treated with DXR or CDDP, used as standard chemotherapeutic drugs in endometrial cancer treatment. Here, CHEK1 is linked to endometrial cancer.